155 related articles for article (PubMed ID: 36310316)
21. An update on the management of pancreatic neuroendocrine tumors.
Gao L; Natov NS; Daly KP; Masud F; Chaudhry S; Sterling MJ; Saif MW
Anticancer Drugs; 2018 Aug; 29(7):597-612. PubMed ID: 29782352
[TBL] [Abstract][Full Text] [Related]
22. Clinical and Biomarker Evaluations of Sunitinib in Patients with Grade 3 Digestive Neuroendocrine Neoplasms.
Pellat A; Dreyer C; Couffignal C; Walter T; Lombard-Bohas C; Niccoli P; Seitz JF; Hentic O; André T; Coriat R; Faivre S; Zappa M; Ruszniewski P; Pote N; Couvelard A; Raymond E
Neuroendocrinology; 2018; 107(1):24-31. PubMed ID: 29518779
[TBL] [Abstract][Full Text] [Related]
23. Dose and schedule modification are required for long-term continuation of sunitinib in Japanese patients with advanced pancreatic neuroendocrine tumors.
Lee L; Ito T; Igarashi H; Miki M; Fujimori N; Kawabe K; Jensen RT; Ogawa Y
Cancer Chemother Pharmacol; 2018 Jan; 81(1):163-169. PubMed ID: 29164297
[TBL] [Abstract][Full Text] [Related]
24. Distinguishing pancreatic solid serous cystadenomas from nonfunctional pancreatic neuroendocrine tumors by computed tomography: A propensity score analysis.
Fang X; Jiang H; Cao K; Li J; Liu F; Wang L; Lu J; Shao C; Bian Y
Medicine (Baltimore); 2022 Sep; 101(37):e30523. PubMed ID: 36123910
[TBL] [Abstract][Full Text] [Related]
25. Mutation-targeted therapy with sunitinib or everolimus in patients with advanced low-grade or intermediate-grade neuroendocrine tumours of the gastrointestinal tract and pancreas with or without cytoreductive surgery: protocol for a phase II clinical trial.
Neychev V; Steinberg SM; Cottle-Delisle C; Merkel R; Nilubol N; Yao J; Meltzer P; Pacak K; Marx S; Kebebew E
BMJ Open; 2015 May; 5(5):e008248. PubMed ID: 25991462
[TBL] [Abstract][Full Text] [Related]
26. International Validation of a Nomogram to Predict Recurrence after Resection of Grade 1 and 2 Nonfunctioning Pancreatic Neuroendocrine Tumors.
Heidsma CM; van Roessel S; van Dieren S; Engelsman AF; Strobel O; Buechler MW; Schimmack S; Perinel J; Adham M; Deshpande V; Kjaer J; Norlen O; Gill AJ; Samra JS; Mittal A; Hoogwater FJH; Primavesi F; Stättner S; Besselink MG; van Eijck CHJ; Nieveen van Dijkum EJM
Neuroendocrinology; 2022; 112(6):571-579. PubMed ID: 34343138
[TBL] [Abstract][Full Text] [Related]
27. Pancreatic neuroendocrine tumor: Correlations between MRI features, tumor biology, and clinical outcome after surgery.
Canellas R; Lo G; Bhowmik S; Ferrone C; Sahani D
J Magn Reson Imaging; 2018 Feb; 47(2):425-432. PubMed ID: 28480609
[TBL] [Abstract][Full Text] [Related]
28. Activity of sunitinib in patients with advanced neuroendocrine tumors.
Kulke MH; Lenz HJ; Meropol NJ; Posey J; Ryan DP; Picus J; Bergsland E; Stuart K; Tye L; Huang X; Li JZ; Baum CM; Fuchs CS
J Clin Oncol; 2008 Jul; 26(20):3403-10. PubMed ID: 18612155
[TBL] [Abstract][Full Text] [Related]
29. Does sunitinib have a patient-specific dose without diminishing its antitumor effect on advanced pancreatic neuroendocrine neoplasms?
Matsui S; Kudo A; Ogura T; Ogawa K; Ono H; Mitsunori Y; Ban D; Tanaka S; Tanabe M
J Cancer Res Clin Oncol; 2019 Aug; 145(8):2097-2104. PubMed ID: 31147832
[TBL] [Abstract][Full Text] [Related]
30. Predicting Progression, Recurrence, and Survival in Pancreatic Neuroendocrine Tumors: A Single Center Analysis of 174 Patients.
Krogh S; Grønbæk H; Knudsen AR; Kissmeyer-Nielsen P; Hummelshøj NE; Dam G
Front Endocrinol (Lausanne); 2022; 13():925632. PubMed ID: 35837305
[TBL] [Abstract][Full Text] [Related]
31. Tumor vascularity on contrast-enhanced computed tomography as a predictive marker of metastatic potential for small nonfunctioning pancreatic neuroendocrine tumors.
Kubo H; Ohgi K; Ohike N; Norose T; Ashida R; Yamada M; Otsuka S; Uesaka K; Sugiura T
Surgery; 2024 Feb; 175(2):484-490. PubMed ID: 38036395
[TBL] [Abstract][Full Text] [Related]
32. Preoperative Prediction of Pancreatic Neuroendocrine Neoplasms Grading Based on Enhanced Computed Tomography Imaging: Validation of Deep Learning with a Convolutional Neural Network.
Luo Y; Chen X; Chen J; Song C; Shen J; Xiao H; Chen M; Li ZP; Huang B; Feng ST
Neuroendocrinology; 2020; 110(5):338-350. PubMed ID: 31525737
[TBL] [Abstract][Full Text] [Related]
33. Prediction of Pancreatic Neuroendocrine Tumor Grade Based on CT Features and Texture Analysis.
Canellas R; Burk KS; Parakh A; Sahani DV
AJR Am J Roentgenol; 2018 Feb; 210(2):341-346. PubMed ID: 29140113
[TBL] [Abstract][Full Text] [Related]
34. MRI-based nomogram estimates the risk of recurrence of primary nonmetastatic pancreatic neuroendocrine tumors after curative resection.
Sun HT; Zhang SL; Liu K; Zhou JJ; Wang XX; Shen TT; Song XH; Guo YL; Wang XL
J Magn Reson Imaging; 2019 Aug; 50(2):397-409. PubMed ID: 30589158
[TBL] [Abstract][Full Text] [Related]
35. Imaging guided trials of the angiogenesis inhibitor sunitinib in mouse models predict efficacy in pancreatic neuroendocrine but not ductal carcinoma.
Olson P; Chu GC; Perry SR; Nolan-Stevaux O; Hanahan D
Proc Natl Acad Sci U S A; 2011 Dec; 108(49):E1275-84. PubMed ID: 22084065
[TBL] [Abstract][Full Text] [Related]
36. Calcifications and Cystic Morphology on Preoperative Imaging Predict Survival After Resection of Pancreatic Neuroendocrine Tumors.
Makris EA; Cannon JGD; Norton JA; Lopez-Aguiar AG; Dillhoff M; Beal E; Idrees K; Smith PM; Rocha FG; Kanji Z; Cho C; Beems M; Weber S; Fisher A; Krasnick BA; Fields RC; Maithel SK; Poultsides GA
Ann Surg Oncol; 2023 Apr; 30(4):2424-2430. PubMed ID: 36434481
[TBL] [Abstract][Full Text] [Related]
37. Preoperative assessment of microvessel density in nonfunctioning pancreatic neuroendocrine tumors (NF-PanNETs).
Battistella A; Partelli S; Andreasi V; Marinoni I; Palumbo D; Tacelli M; Lena MS; Muffatti F; Mushtaq J; Capurso G; Arcidiacono PG; De Cobelli F; Doglioni C; Perren A; Falconi M
Surgery; 2022 Oct; 172(4):1236-1244. PubMed ID: 35953308
[TBL] [Abstract][Full Text] [Related]
38. Management and outcomes of patients for non-functioning pancreatic neuroendocrine tumours: a multi-institutional analysis.
Du B; Wang X; Zhang W; Tan Q; Wei Y; Shao Z
ANZ J Surg; 2022 Apr; 92(4):787-793. PubMed ID: 34723424
[TBL] [Abstract][Full Text] [Related]
39. Efficacy and safety of everolimus and sunitinib in patients with gastroenteropancreatic neuroendocrine tumor.
Yoo C; Cho H; Song MJ; Hong SM; Kim KP; Chang HM; Chae H; Kim TW; Hong YS; Ryu MH; Kang YK; Kim SC; Ryoo BY
Cancer Chemother Pharmacol; 2017 Jan; 79(1):139-146. PubMed ID: 27942928
[TBL] [Abstract][Full Text] [Related]
40. Circulating cytokines and monocyte subpopulations as biomarkers of outcome and biological activity in sunitinib-treated patients with advanced neuroendocrine tumours.
Zurita AJ; Khajavi M; Wu HK; Tye L; Huang X; Kulke MH; Lenz HJ; Meropol NJ; Carley W; DePrimo SE; Lin E; Wang X; Harmon CS; Heymach JV
Br J Cancer; 2015 Mar; 112(7):1199-205. PubMed ID: 25756398
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
